Biogen, Inc. and Eisai Co., Ltd.’s announcement of a three-month extension to the PDUFA goal date for the potential Alzheimer’s disease therapy aducanumab cast a spotlight on what is usually a fairly mundane regulatory event: a three-month extension to the goal date.
Analysts greeted the 29 January 2021 announcement of the new 7 June target with a degree of optimism, noting that the agency could have simply issued a complete response letter for the biologics license application
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?